1. Potential Theranostic Boron Neutron Capture Therapy Agents as Multimodal Radiopharmaceuticals.
- Author
-
Jalilian AR, Shahi A, Swainson IP, Nakamura H, Venkatesh M, and Osso JA
- Subjects
- Boron, Boron Compounds therapeutic use, Humans, Male, Precision Medicine, Radiopharmaceuticals therapeutic use, Boron Neutron Capture Therapy methods, Head and Neck Neoplasms drug therapy
- Abstract
Boron neutron capture therapy (BNCT) has been extant for decades and continues to be practiced in many centers around the globe. Most of the active clinical trials utilize boronophenylalanine as the drug containing boron atoms. The important aspect that has been added to the BNCT practice is the use of an F-18 radiolabeled analog for ascertaining targeting and monitoring follow-up studies. The recent widespread application of therapeutic radiopharmaceuticals, especially peptides (somatostatin analogs), prostate-specific antigen-binding ligands, or immunomolecules, offers the ambit for invention of new tumor-specific BNCT agents, especially for BNCT-susceptible tumors, that is, locoregional cancers such as head and neck cancer. Such BNCT agents, when radiolabeled, can enable simultaneous imaging and/or therapeutic applications (depending on the radionuclide used) through multimodal approaches. Development of boron-rich moieties such as sodium borocaptate and neutral carboranes combined with tumor-targeting moieties can lead to a new horizon in BNCT. The review covers various aspects of drug design, tumor targeting, and possible future radiopharmaceutical development for multimodal theranostic application in humans.
- Published
- 2022
- Full Text
- View/download PDF